TrialCancer medicine2021

Multi-institutional, prospective, randomized, double-blind, placebo-controlled phase IIb trial of the tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine to prevent recurrence in high-risk melanoma patients: A subgroup analysis.

Robert C Chick et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.